0001193125-24-066825.txt : 20240313 0001193125-24-066825.hdr.sgml : 20240313 20240313160752 ACCESSION NUMBER: 0001193125-24-066825 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240313 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spero Therapeutics, Inc. CENTRAL INDEX KEY: 0001701108 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 24745973 BUSINESS ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-242-1600 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Spero Therapeutics, LLC DATE OF NAME CHANGE: 20170316 8-K 1 d809069d8k.htm 8-K 8-K
false 0001701108 0001701108 2024-03-13 2024-03-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2024

 

 

SPERO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38266   46-4590683

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

675 Massachusetts Avenue, 14th Floor

Cambridge, Massachusetts

   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (857) 242-1600

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   SPRO   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On March 13, 2024, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, or incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits.

 

99.1    Press Release, dated March 13, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 13, 2024   SPERO THERAPEUTICS, INC.
    By:  

/s/ Esther Rajavelu

      Esther Rajavelu
      Chief Financial Officer and Chief Business Officer
 EX-99.1 2 d809069dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Spero Therapeutics Announces Fourth Quarter and Full Year 2023

Operating Results and Provides a Business Update

 

  •  

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024

 

  •  

Initiated enrollment in PIVOT-PO, a pivotal Phase 3 clinical trial of oral Tebipenem HBr in cUTI

 

  •  

Submitted IND for SPR206 and received FDA clearance to proceed with Phase 2 clinical trial

 

  •  

Reiterate expected cash runway into late 2025

 

  •  

Conference call and webcast at 4:30pm ET today

CAMBRIDGE, Mass., March 13, 2024 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

“2023 was a productive year for Spero and we have been focused on execution across our programs” said Sath Shukla, President, and Chief Executive Officer of Spero. “We are well poised to unveil top-line data for SPR720 Phase 2a, which is expected in 2H 2024, and our excitement is fueled by the hope it may bring for the rare disease community grappling with nontuberculous mycobacterial pulmonary disease (NTM-PD). On tebipenem HBr, engaging with the FDA and in collaboration with our partner, GSK, we are actively enrolling patients globally in our Phase 3 PIVOT-PO clinical trial. Positioned as the first oral broad-spectrum carbapenem in the United States for cUTI, we believe this product has the potential to change the treatment paradigm for these patients and underscores Spero’s commitment to innovation. We reiterate our expected cash runway into late 2025 based on our year-end cash balance, along with tebipenem HBr development milestone payments from GSK and our disciplined capital allocation.”

Pipeline Update

SPR720

SPR720 is an investigational novel, oral, first-line treatment for NTM-PD.

 

  •  

Top-line data from the Phase 2a proof-of-concept clinical trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients is expected in 2H 2024. The trial is expected to enroll treatment-naïve or treatment-experienced participants with non-refractory NTM-PD due to Mycobacterium avium complex. The primary endpoint evaluates changes in bacterial load in sputum samples from baseline to the end of the 56-day treatment period. Key secondary endpoints include assessments of clinical response, quality of life, pharmacokinetics, and safety and tolerability. For more information on the trial, see ClinicalTrials.gov identifier NCT05496374.

  •  

A paper Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection (Nicole Cotroneo et al) was published in Journal of Antimicrobial Chemotherapy in February 2024.

 

  •  

A paper Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720 (Kevin Winthrop et al) was published in Expert Review of Anti-infective Therapy in October 2023.

Tebipenem HBr

Tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP) to help patients avoid hospitalizations or reduce duration of in-patient therapy.

 

  •  

Spero commenced enrollment in PIVOT-PO, a global, randomized, double-blind, Phase 3 clinical trial of tebipenem HBr in patients with cUTI, including AP in December 2023. The trial compares oral tebipenem HBr with intravenous imipenem cilastatin, in hospitalized adult patients with cUTI/AP. The primary endpoint is the number of patients with overall response (a combination of clinical cure and favorable microbiological response) at the Test-of-Cure (TOC) visit. The trial is expected to enroll approximately 2,648 patients, with enrollment completion anticipated in 2H 2025. For more information on PIVOT-PO, refer to ClinicalTrials.gov ID NCT06059846.

 

  •  

In July 2023, Spero received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design and size of PIVOT-PO. The FDA has indicated that positive and persuasive results from PIVOT-PO, supported with confirmatory evidence of efficacy, could be sufficient to support approval of tebipenem HBr as a treatment for cUTI, including pyelonephritis, for a limited use indication.

 

  •  

Under the terms of its license agreement with GSK, in December 2023, upon dosing the first patient, Spero earned $95 million in development milestones payable in four equal installments over two years. Spero also received a $30 million development milestone payment following the SPA. Further details on the agreement with GSK can be found here.

SPR206

SPR206 is an innovative, investigational IV-administered direct-acting next generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in preclinical studies.

  •  

An Investigational New Drug (IND) application has been cleared by the FDA to advance SPR206, to treat MDR Gram-negative bacterial infections, into a Phase 2 clinical trial in participants with hospital-acquired or ventilator-associated bacterial pneumonia.

 

  •  

The results from the Phase 1 bronchoalveolar lavage (BAL) study of SPR206 were published in a paper Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects (Keith Rodvold et al) in Antimicrobials and Chemotherapy in July 2023.

 

  •  

A paper Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment (Jon B. Bruss et al) was published in Antimicrobials and Chemotherapy in October 2023.

Corporate Highlights

 

  •  

Satyavrat “Sath” Shukla successfully transitioned to President and Chief Executive Officer (CEO) of the company, and a member of the Board of Directors in August 2023. Mr. Shukla had previously been Chief Financial Officer and Treasurer of the company. Mr. Shukla succeeded Spero’s prior CEO and President, Ankit Mahadevia, M.D., who became Chair of the Board of Directors in August 2023.

 

  •  

Esther Rajavelu was appointed as Chief Financial Officer, Chief Business Officer, and Treasurer in November 2023. Ms. Rajavelu brings over 20 years of experience working in the biotech and financial sectors focused on growth strategy, M&A, and financing.

Fourth Quarter and Full Year 2023 Financial Results

 

  •  

Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the year ended December 31, 2023, or a diluted net income per share of common stock of $0.96 and $0.43, respectively. Net income for the fourth quarter and net loss for the year ended December 31, 2022, was $26.8 million and $(46.4) million, or $0.55 and $(1.23) per share of common stock, respectively.

 

  •  

Total revenue for the fourth quarter of 2023 was $73.5 million, compared with total revenue of $47.4 million for the fourth quarter of 2022. The revenue increase for the fourth quarter of 2023 was primarily due to $71.8 million in collaboration revenue related to our agreements with GSK and Pfizer. Total revenue for the year ended December 31, 2023 was $103.8 million, compared to $53.5 million for the year ended December 31, 2022. The revenue increase for the year ended December 31, 2023, was primarily due to the aforementioned collaboration revenue related to our agreements with GSK and Pfizer.

 

  •  

Research and development expenses for the fourth quarter of 2023 were $16.6 million, compared to $15.1 million of research and development expenses for the same period in 2022. Research and development expenses for the year ended December 31, 2023 were $51.4 million, compared to $47.6 million for the year ended December 31, 2022. The increase in research and development expenses year-over-year was primarily due to increased clinical activity during the period related to the ongoing Phase 2a clinical trial of SPR720, offset by personnel-related costs.

  •  

General and administrative expenses for the fourth quarter of 2023 were $6.4 million, compared to $6.5 million of general and administrative expenses for the same period in 2022. This year-over-year decrease was primarily due to changes in personnel-related costs, offset by increased professional and consulting fees. General and administrative expenses for the year ended December 31, 2023, were $25.6 million, compared to $36.5 million for the year ended December 31, 2022, with lower expenses in 2023 compared to 2022 primarily due to decreases in both personnel-related costs and professional and consulting fees.

 

  •  

As of December 31, 2023, Spero had cash and cash equivalents of $76.3 million. Since the year-end closing of financials, the company received $23.8 million, the first tranche of the $95.0 million in development milestones from GSK. Based on its current operating plans, Spero expects that its cash and cash equivalents, together with other non-dilutive funding commitments, will be sufficient to fund its operating expenses and capital expenditure requirements into late 2025.

For further details on Spero’s financials, refer to Spero’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) today.

Conference Call and Live Webcast Today at 4:30 pm EST

Spero will host a conference call and webcast today at 4:30 p.m. ET. To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13744458 or click on this Link and request a return call. The conference call will also be webcast live and can be accessed through this website link, and on Spero’s website at www.sperotherapeutics.com on the “Events and Presentations” page under the “Connect” tab. An archived webcast will be available on Spero’s website for 30 days following the presentation.

Tebipenem HBr Research Support

Select tebipenem HBr studies have been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.

Government Agency Research Support

The views expressed in this press release are those of the authors and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

Department of Defense

Select SPR206 studies are supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Joint Warfighter Medical Research Program under Award No. W81XWH 19 1 0295. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

National Institute of Allergy and Infectious Disease

Select SPR206 studies have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00022.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need.

For more information, visit www.sperotherapeutics.com

Forward Looking Statements

This press release may contain forward-looking statements. These statements include, but are not limited to, statements about the design, initiation, timing, progress and results of Spero’s preclinical studies and clinical trials and its research and development programs, as well as the regulatory path forward for tebipenem HBr and potential FDA approval, the potential commercialization of tebipenem HBr, the potential receipt under the GSK license agreement of milestone payments and royalties on future sales of tebipenem HBr, and Spero’s cash runway. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether tebipenem HBr, SPR720 and SPR206 will advance through the clinical trial process on a timely basis, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and clinical outcomes; whether the results of such trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; Spero’s need for additional funding; the ability to commercialize Spero’s product candidates, if approved; Spero’s ability to retain key personnel; Spero’s ongoing leadership transitions; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

Ashley R. Robinson

Managing Director, LifeSci Advisors, LLC

arr@lifesciadvisors.com

(617) 775-5956

Media Inquiries:

media@sperotherapeutics.com

Spero Therapeutics, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands)

(Unaudited)

 

     December 31,
2023		      December 31,
2022		      Change  

Cash, cash equivalents and marketable securities

    $ 76,333      $ 109,107      $ (32,774 ) 

Other assets

      106,057        15,695        90,362  
  

 

 

     

 

 

     

 

 

  

Total assets

    $ 182,390      $ 124,802      $ 57,588  
  

 

 

     

 

 

     

 

 

  

Total liabilities

    $ 75,496      $ 48,868      $ 26,628  

Total stockholder’s equity

      106,894        75,934        30,960  
  

 

 

     

 

 

     

 

 

  

Total liabilities and stockholders’ equity

    $ 182,390      $ 124,802      $ 57,588  
  

 

 

     

 

 

     

 

 

  

Spero Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

 

     Three Months Ended
December 31,		     Year Ended December 31,  
     2023     2022     2023     2022  

Revenues:

         

Grant revenue

    $ 1,698     $ 1,087     $ 7,046     $ 4,930  

Collaboration revenue - related party

      71,603       46,076       95,802       46,076  

Collaboration revenue

      223       278       933       2,503  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total revenues

      73,524       47,441       103,781       53,509  

Operating expenses:

         

Research and development

      16,558       15,089       51,440       47,593  

General and administrative

      6,433       6,495       25,554       36,483  

Impairment of long-term asset

      —        —        5,306       —   

Restructuring

      —        (67 )      —        11,630  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

      22,991       21,517       82,300       95,706  
  

 

 

    

 

 

    

 

 

    

 

 

  

Loss from operations

      50,533       25,924       21,481       (42,197 ) 

Other income (expense)

      1,046       847       3,923       (4,218 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income (loss) before income taxes

      51,579       26,771       25,404       (46,415 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Income tax expense

      (387 )      —        (2,598 )      —   
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income (loss) attributable to common shareholders of Spero Therapeutics, Inc.

    $ 51,192     $ 26,771     $ 22,806     $ (46,415 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss per share attributable to common shareholders per share, basic

    $ 0.97     $ 0.55     $ 0.43     $ (1.23 ) 

Net loss per share attributable to common shareholders per share, diluted

    $ 0.96     $ 0.55     $ 0.43     $ (1.23 ) 

Weighted average shares outstanding, basic:

      52,999,491       48,715,409       52,703,467       37,585,075  

Weighted average shares outstanding, diluted:

      53,108,270       48,942,616       52,989,030       37,585,075  
 EX-101.SCH 3 spro-20240313.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 spro-20240313_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 spro-20240313_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 13, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001701108
Document Type 8-K
Document Period End Date Mar. 13, 2024
Entity Registrant Name SPERO THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38266
Entity Tax Identification Number 46-4590683
Entity Address, Address Line One 675 Massachusetts Avenue
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (857)
Local Phone Number 242-1600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol SPRO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /F ;5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #Y@&U8Q QP@.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$GV!TSJ2\M.&PQ6V-C-V&IK&CO&UDCZ]G.R-F5L#["CI9\_ M?0*U.@C=1WR)?FC MVB/4G-^#0U)&D8()6(2%R&1KM- 1%?7QC#=ZP8?/V,TPHP$[=.@I0556P.0T M,9S&KH4K8((11I>^"V@6XES]$SMW@)V38[)+:AB&K-]9++F]6W!FZ)JMC47_$'<\8_)]8??5=CUQN[L M/S:^",H6?MV%_ )02P,$% @ ^8!M6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #Y@&U8+(C-.6D$ Q$0 & 'AL+W=O -QL)_\?'SR')O!7JI7O>7X$:#61N8I'R0!&=)PE3[_<\ MEONA0YV/&W.QV1I[PQT-,K;A"VZ^9H&"EENJ1"+AJ18R)8JOA\Z8WMW['3N@ MZ/&'X'M],3'L=6"3C^.8HZY3/MP-/K M#_7'8O(PF173?"+C;R(RVZ'3=TC$URR/S5SN/_'CA K 4,:Z^"3[0]^VYY P MUT8FQ\% D(CT\,W>CH$X&="B9P;XQP%^P7UX4$'YP P;#93<$V5[@YJ]**9: MC 8XD=I561@%OPH89T8/,LPAR(:P-"+3U CS3F;I8;4A:@/7P$-L5S<\"MX? M!/TS@D],W1#:NB*^Y[?_.]P%MA+0+P']0J]U1F\B=UR1O\8K;10LX=]U1 >% M=KV"S>L[G;&0#QU(7,W5CCNCGWZ@7>]7A*]5\K4P]=$8HA<5$7R,V::.#A^_ M9K'F"$>[Y&BC.L>UFP")8C&L8<3?R&?^7D>$*WF>1WL>I5X?P>J46!U4K,RO MY7O&ZUCPX?WKSPA$MX3H7@81<"6DS?.(P-M2RX,KE=G=E-Z]$JUWR;+-^4;8 M! ?&9Y;4@N$ZBV Z?R'+3]/Y.)A^7Y[<((C]$K%_">(L#:7*I"I\ M@2P,Q(],9 [I!EDGHUIF7/AABM#=EG2WE] ]BIB3YSQ9<54'@FM PE^W^GZW MB_!0KW)4[Q*B)7LCLPBR3JQ%> C:>;X&R7;WNMVY];K]%D9XXOGT$L)Q%($? MZJN/"_(%^I&7M'8I&R2[O0YY8EJS<)MK;HPFXQU/<\S9:%4"*.K@..]R+VMY M<4G:-EMP;"D51E@5 8J[^/>$$]N2BBSEOKZ&XG(3EJR4B#9H^*K*0"\J#27< MX=T%ND#)G4C#^O7&-9_&&%I5'2CN[]^C!5(;J%Y_BNRLIS0H>CYMW6)L5=&@ MN-<7:SB&K>YY%%S@YWZG]PN&4A4)BKO[%QE"5(*M3#&3:Q#QV_XU;'H\C*BJ M"13W[F]*&,-3"$V2Y.G1X'0M%2[4M/^A52&@N(LO9"Q"842Z 2*13;?%N_)2M9F6X/ (IB_8"25Q_NX'Y<1F[Z%6Y9N^-E] M9(/0\WCQ,/X=8ZK,W;_(W*<)5QL;I=] :HNK$O&TMJ#28/@V01S3P[ ]L\$ MV*;#$S6)^1J$O)L>Z*K#^?S0,#(KSL0K:>"$75QN.8/DMQW@][64YJ-AC]GE MOR2C?P%02P,$% @ ^8!M6)^@&_"Q @ X@P T !X;"]S='EL97,N M>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG M:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1< M>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6 ME :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,H MH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+ M3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC M%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8 M\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W M5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76 M^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1G MA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ M;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^: M0ERHY_U=3_ 102P,$% @ ^8!M6)>*NQS $P( L M !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,. M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MY MEJ6R!F_236P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88 M!.R '<(Y_A^[<#K3P&]'@!6^AC(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 > M"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DN MR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% @ ^8!M6"0> MFZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9 MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( /F M;5AED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"% MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/ M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4 MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A MLO7L^T%.6X.^D&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( /F ;5@LB,TY:00 #$1 8 M " @0X( !X;"]W;W)K&PO$0 >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #Y@&U899!YDAD! #/ P M$P @ '#$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 .."0 ) #X" -% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d809069d8k.htm spro-20240313.xsd spro-20240313_lab.xml spro-20240313_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d809069d8k.htm": { "nsprefix": "spro", "nsuri": "http://sperotherapeutics.com/20240313", "dts": { "inline": { "local": [ "d809069d8k.htm" ] }, "schema": { "local": [ "spro-20240313.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "spro-20240313_lab.xml" ] }, "presentationLink": { "local": [ "spro-20240313_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-03-13_to_2024-03-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d809069d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-03-13_to_2024-03-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d809069d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sperotherapeutics.com//20240313/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-066825-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-066825-xbrl.zip M4$L#!!0 ( /F ;5@6NQO6^0X +!@ . 9#@P.3 V.60X:RYH=&WM M7.MSXKBR_YZ_0L7>.9M4!; -(4 RG,HRS"ZU,TD*,G6V[I0422#+9DU3-@-&KU?U3OR3Y_-^3L4_NF%17[^_N2Z1X;>%J6L449*A6A M%I/<3=M-?!Y\GVMV7S&-[$:C43:E:=6EFMD CF55RE@\H(JEU54H159=A4P* M/6*2ABS2W%4E5XQQ E6K8F>3F"B^BA3HWB[_\?5+WQVQ,2WR0&D:N-E D99K MR6J4H32MR)6H.O;I W-(:F0-)NOJVE W@!FS/W[I?9E5UZOKSZJ6M:2!&@HY MIAHP@SV=%"VGZ-1RG10!$W,=I1C9U$^]6+$S7L+@_*&I+G 12[T%;":5:^6X M,*FZ'BV(\P+BG5$//C37/FO5B[^?E^.O!^=CIBG!YD7V=\3O/A;:(M LT,4; MP&>!N/'3QX)F$UTVW96A53GND!!R/A#>M'7N\3NB]-1G'PL>5Z%/I[@ 6*%% MSOFDB;693+YSSV-!_!VJ7,;H)P$=8UO&FQ=C%GCP3W_VZ6U"P43WV!"*(VFX M^R?BM&A5BG;E3RUR3P7"O8\%/KDK.I5&H36DOF+GY;F1ED;&%K\9HOZ$X?_L M!,"::1O&E]3O!AZ;_,ZFA1Q]:RH\CLZ6!4OHU+)MJ[Y,7WF!39(-F00UQA0\ MXZIN*K/P8*SG5!IF)%13'PN*CT,_^VTD<9*H3HJIPBA-E)<64^E*@4C8/$@Y MF>W<#,VS$I&,'\VZ:2;L-=+:@KUI,V:$E3UR#W\8V3\H52Z\[!$6M-2?J&:M&6UIRUG9C%9O3=VT)!LV&Z<\QYV,FS/NE?/+ MKPS+%#YRBQ5;%:G/;X.F"W-ALC!??L\]/6K62R<\.,O5]=E0GXVIO.5!$;\W M"8VT2'^1_':4_(3=A6EGJ"N+(V9*P32'61=:A,WTC'WI\T;/F:*7+)[TA-C&IR9LON8[H'PO;,5XOEVV;WI?"+]FXN;3G\] M.=8+D=/OM+_UNC?=3I]<7'XBG3_:OUU<_MHA[:NO7[O]?O?J;-[UI8 MU-Y1\714[&4=@Z;I=2YO2*]S?=6[>7V]L?;#EL#.AH!^0&[@* M9<8%0A51(7,Q"O((#PC7BH!&@44I%_7=.]#7 'T7QAR<:SKP&7&9[ZN0NIC7 M+%@%\QQ2STN?DZ&2J;K"]VFH6#/]\C!$_.18Z7Z 8/\?,$=DYJ[U$^X&D]TL5+2VMFN=4KB4NU\-^?EA$29EH;T MEA4'DM'OF,*$\+Y)[P2@8&ONV$8\3Y<.T)^8I- NEN,-AYTU?!0PW M\^D]F,1EHX=30IY[VT@_@_AB]5=@YV?N,R@;@*)YNKZO8@+)+E;J3JWV#^+- M#9UTDRR8:YBQ,Z-."JUJK5@]:5BU>N4A3CW#\JWO9_4^U5;O)5(^- L>8PZS MFT/^ D]?>=P$(X]R).QG( Y\!YY73D>Q/7P-W+^ND-IB/.9*_0@R0?5&XF7[ M7RN.;JE7ZI=(9QSZ8LKDJ\MD7J>22U&:B<;H/?@/W;ZWZD4:"G=Q(T^LO3B" MU?J/ZPBFR^QU([\-]O_"\R13*OGX K&7O8/MKQ5:M=,3\I4J1=U1I)B&:/+B MC@71DC]YO"E27Z;,>3)EIW:A95?/5;1BL9V>?%BMT?0(O)4(%M=G7PBY(0GT M*!7SDI)MP]2/N@QWD>EIHM>EX(+EW^V1!&K?F2EY#X,'-H8CG"V/JF,'+ M07"5[%[<2J;][>:O)\R\%C!]_W]Y^*2(<,:I!D0UCEUIO$T_?0,K#Q-F8<8K ME Z'E*?L ES(\WO,!$&!IJIHQ\Y?#L$&1,4\M&22%:X$(_,].]%#[8IV<*^."S<"0"1@+CEAYCT.!'Z(40"K !O'ILO=I E74!U7;#=LT"[M5/ M3H\V'1>:#?Q%@'"ND?!=H^ :&!RGZA0!*-;[]L&+;$AN C.8L!%SOQ,(J@D- MP7" 2L! >R F9,!\<4_XT!1^!D-#ZL7?R9#[B%BN +Z:!1[S<%]0\7'D:QHP M$2E_2A1@0@VGIF720 R #['C+^(N<_GV"/J1A ;3M&P(OK>XQW9HS#B&E*JY MOSWK-#+8J^>?N?NS$& YUEB(1;8R(8653OZ'LY6:<]TR_H_D&N2%(7H4)"&8 MVMG?& CA#RC(2@-B\DO=07XW3JO5L^65OL&B+$;.9%ZT9&<%OG#"J]!*> /, MR#.'A+F-[UX$<*DZ)PE4]?Q^,VXS']JGI/VY1YR*58**CPEMW_&[&;]]T+$N M<#NX_0H*"K24_WS@K;PE\,X8 UW'G%E&KEVE1=O)@7?NA$0&W:I5BFN^HW>_ MZ+V6##4OGOTU1[K0<,JKX? )[M36**Z^)10#@XINCD,;=;%=]8K.X>!H.TS' M==]1_:RH[BH5,?DBV#[Y9V.[PHK50W<[;"=U-V-[[Z%#S@&*?7DF(1H(5QT7 M-"LU\>UA!NM=^1\_R_]^5F3/2:PM0NHU4QQQS8HH M-HL/=+HCXOI4J9?)JCZ5A:^\0WDC*2[/5]^8[$_'4'2H7FBG^(U*ZS(Y)VG MS1)[].JR ^L">@ HFIF@>4OXPVV!;HAS8Z,ZM9V!42<[I%MKA1:Z9\"AOA;N M]V/R/Q9@S28AE>2.^LO;CZ^4[%_'BD0]Q*MS!SZ&_(@ M/L@=I_&LD]077 0+[1H/Q';/RY_N\ $D MX7[=2ECRI>V,$8#.K"8 72!,)!0I9FH!PY)-$WR1 C?147S-&1EDQO*G./@] MAZ%1. '0!R62W7$%[0#*-' QR4==%P] 8V5\I8)'I:?B[1)O71A6.:19&);' M:(ED'-_?-MP_[4)TO!>7[,@='*S&(1LOP1!_ROD= P:"!K_#OZ=358COP1R< MCS(7!0)2(9L_-ITZOV+[Z\N7B MNM]IIE]^Y/R6;:],!CLC4;SAYT-1OCGKYEGSDERRDMGY/(]_9:.:B' M/.=XFCVF(E^;8R!7H("25!2H$?(YTS!M 1H/"TKD,=FEVCYT\55 S(7#>/VE MMPZ/21_?Z(/W/;-7^AR3;N"6R"$J-92,8YTE-LH\V6='X"*H"'0B!?6(1U\D M*&<*"ID& 6A0U^QG:_PY9@DJXG@3.I*@A/^.S,4OPYMAY/L$;T>26(M_8B[# M0Q$QE17;4%DID0O0Y&&VFST_*EC\820#KD9($CH+(S[@FC0:)9O O)@6I0=N MQ\5747=E+_I_/,A>Y&.,.4V])..5(- )0MQ,W/RZ.)--TR!J! ;>F, ! S<, M+*N7BFC(?>8E C(S"91T> O M]&Z!)NS(YW3 _;@GTS?5F9&$=LE716S;3-YVP&X>.DXU+P\\N!<"TP6?( M7O^"W$33GAR-,*8>^_V&Q[5SG>/8V41GA^M!^)YQ0K!-._5.4N\X+C1&!HF@ M0YVXS'C!UPA&#(_16P%_P4\.@B$QMRR ->7/7V4@/HP=@8I%DE4$879,\Q) M<^"K[[AS\FY9SAHERWZSEF5F/\SI5MSQ2*%L-(3:PIKL;Q_N+:)I]3[%)\C;F[3DW@/8#B"UV@ X.XCT@\^&5D\]M=FTJ:W9M&M5LUR;I M_#GSFLOX6;GC@O;^D:FT=0FUE?DR2N(7L7EUJV'5&AZ;-!IV::3'9F,5[%\Q.1H M)IN#3#DD^MU?+R]NOO4Z3XE%3'\\P M_:,T>%YOD7S@4 M9];^CKA,'(EM0X$5*3DO\J?$I1&FT4R($[]H!X>!\$3!Y*% Q&_[&# (78:I MDVW.8205T(.. FACN@-1C82$B7D/N<1OUJ8M6K$%/^4$U\7V=FWMA<4MNUES MEF%/1)R\HG%-YC>S)97X;5'-5>9LYXVK+09?_QJ?IUI17 1KS*@IFK>C^ZWV M*E9Y-6;W(JJ]]FF,^2_3YC/!ZI'' S8DY!]I2LJJ3#K*Y$5Z]"]ZQ_SHA4\' MO%%0/&.?K26!O OC]831'G$VS.7\K\S]SSC;'9?]$BGPV"'02HJV<=;/R_$+ MT\V[U%O_#U!+ P04 " #Y@&U8X7:^0):FH$KV>#<>"/7,,C,D; ^8S,W[UK;: MMN[(:D^W9R'G\%SO\='1Y=GG]V];7SZ>W)UOL MYO:OLY/?MES'$X6!G?T8WWSEV,/BP M6ZP[WA;CKM/WX 6B%VS1,E?1;4/N]QVO$,C1A](HV&/F]XX, CG4EWK2"PK* M^:_X4$Y^[_&AXTX^W#I#H=B%N&/7+W[9\!'+K8/_PX.3[P.DX M <,=L_WWAP?[[Z]PRXL@*%?6"$*7<$(PW(R$+]GM0/A\),+ Z2K6]CP9>EUX M\J,,_6# _C?D/MS/N&>SCZ'KLK\$]UFE5*D^!/4Z\98"^A* YH'C]=FU4*$; M* +MRI=CQX9G.3L,%1"$4NS+R.:!B,%,G6X*!$3M#-!S,&\=_.IUU&B/WH+D MVCX\.XG>=7AY?7QR70#*/&M?W9Q\B'ZX=V.S6-AB^C6_;96VV-')V=E5^_CX M].)3_/O-5?LH^OWKZ?'MY]^VRJ72O[8T/-=,!1-7L-_8UHCW1:'C"_ZMX'@* M4/*!CZ5CFQN/HX?K_THV=7L\\\?JO[;8GP;S@)3X%#2?_/I+N=9:]%AYYK$% M"Z1?-'TOGL[47PUZV?3AL.4DM2*F#_9/#RX]%OB\^PW^YC-X,TH0!L3"6<^7 M0W9S==VLE-C5@"O!*AQ _WAY<1M+D($3B((:\:[XX,D[X!UXYT,WC'PI>P7X MMRN!NT;!_GM\XL#\#Z!QN,LK#/0/J3:*4''[NX/2]<'9O;\[D1\!HLK2R&BW<#6!G K'Q&$5 #WCJ% M5P);T"'#?Z[Q/\@>B]FMD7';V^.V4\\)'(Z4(SQ?NBZ2,A+1@Z1X=?KGY6WA MZM**B)>SD3.6 ;"*YLTJZP+K.EVXH#E(]O(YZ<,/MZ+CC(0GANSSH8^+=;_< MGF;DFI'KP^1Z$W:&3H#D>GIQ3!H"]$&EU"!9[(NN +D,MM!Q&X@/;"$.TAAT M" ,)WQ7PASL'K":C.F;($\D/K=J,_C+Z6TY_UP(DH8^6:ZQQNUP-F!]Z=WP" ML@R(S<4_@P:NWR?2TG9Y1E-OFJ:.I-<3/AJ.0$O@Q*$HNQ,=H*N \8#5/E1+ MHR$[N05!9O/)BC2U;@_UX*A]?GA]>OSIQ&+G7*FBI?%YSOWN@)6K%MF<^AJ< M2;V\IW^>=V,M=NIUB_JOVQ=:!Z\RS=N,/DR P'_)\?][Y3CWD/'?8*.N_!L>/@8 MM-BP(WR-H6J9, OXQ7M'VI.V&?@]G MH+%#P &X0@0_J6,Z;TW";,#A3QTA/)8Z'_%==$-$'.-=7P+\@!)\5=_G0X5K M[.XQQ1V;W7# U,T@_.9RBUWA2>#)PF'CVX\&CNBQ$_TN6.6RUW.Z@%'9TR 4 MF0;W*[AI<+YW I \D@[" "(Z],;"<1\V<@%Y!?0_(QM7NZ':ZDA[H1:#IX$/ M'+7($]-GA]L4W[NPB+:Q@2A"X<*-G0F1QD".!',".*8)Z_A(KA'1((7FB'(5CM$P88&Z%[W-=V#?B400B$TPU=&2HVG'1E0JZCT!U*C_N3B-0?WORV M]C9WBM'NT3-/F^[@=GI]WH\!0%C1],+=HE4/[@3O2 P(P6'3'7340/J>@(<_ MW?QA(97@^7 B(W=BO!!\9>3Z0V1?[&RCQ)M8-KB*[(KJ1P$ M#AE*:?YT?)"ZY*5T?,EM>"&1, ]VD.1S^& MMM01K@-B!VZ#8S9L MR@UQC) "44@B%9=\"]OJ#KL5Q"%'';Z0]1KA$)P'8C M=!!V0Y 4ONI*8 I-[DCLC3U%Q.'HE\#+'9!(8T)_D0$C^+'QHFGQ80.FPPW3 MX@,/HAN%0 &$6(QN?#&<'%KAP .NC EER@$T IJ !LDC5 G@L&-B1'2&/8! M8HFY""BXZU!<"($?.>AS GW(KMZJD2'WB,/==8C#_<.#*]@%A:=FHIE+%'%C M3I!X)M;U^J+%B0*9,U+R M.;12BFBE1^"G;@&%H)7R"N92:LN_.N'0W1O'1X.*;.'NT1YP0)YSA(W4P\O@ MPPY!R<#FP ,[3TPET/1\#/\E-PO]"U=\UY@9^(S<3BA1>"Z;FC#GM&Y4DKK5E@TIEPP)D;@SH"J!O?$10,3 M_NHZ/;A@_"[Y#6#6/AQ2L^(]$4PT84L7+(N.@X\5V4B\ENS_\TJ)_I@5])!R/3BYN3ZZ?FN[.E->&*Z\V$!;P)#M!SY1WB9LB>\IC MP]!'_A]*6[C$ABL)O91_%R)Q80K2+E->LX^TG##3]A]B#+3X%93K"( MR$_0_ C8-3P(\!I2+QB& 5--ARMUJ!6>N 0S P"F.-P*5/X18"&PCL 8CG'M,21J8EF)O8*F!]I7(!S1S$1YB.>. MM1]!6GAA4&7'6"\4T^V& 88')O!F3XP&OA, =-OMJQVTI@;"':5B)!%/;Y6'@HVL%ZT'_M.BY7 18&XE(I?L3 MJQVZP0*@WK>O%OM=^9RCXZA>2"#"'J>?EF-@2C?Q9]@V1[@[(%\B5H_1U U] MK6)Z0,;@P "1&Y-'NK(_Y1;M8#)N)0_MX; %2%$,)1S!ZC-QA.W;RZ,=-G:4 M$TP[Y/G< H^5<9./YTP5CD;2#Z)RJ*[T>@ZRNO0G M(&0POXRE"+ 983Q7"^X)71ML.G@6KSDFOV3>I,70>)&^H3SQ=#Y@5N-,&W(6 MW<.9"\J#S$(E(K10&BN3$IF46"XEOA 3DY\A_"'%51Q@%/ Q!!H"B7P@RJ<$ M]*RU Y( U#VS@?> .).P1W/>$G<^]:]4U*@! %\4)O&]A0A.\4#XA M \/QJ R$"0RSPF]@&6D%K 89!(^(X@I%DL_A >LZ M3_1\[\GLKBOIB16ED\#Z(#*-0AI)=S*9B/M?A(>#&K-MH>.YUA;;R; MK,7MTXOC'4:%5MH&(8:DHC8J,4\*N-"* Z.(VV,J.]=BQ*(4'QI R*+YW#2/ M+BXGI"(&GN@BS+E@INNW*Y&F(9:)P?. %Z'P@7Z?@,^ -TVTEHP/M4H1?90:>I(-6,-PB<]UEP-QA,X"\8F;H)._\!SE28 M9T!.NY;V6((S9')H.J$PE2K3)7KI?%F42(@]V%6,J(SCWB['1;FRFZ3"8K8$ M8YH_5$2EI W&P" Z_8(&/=WJ"]1JSG#$P=>G4,;O0.V'17;HAPJ#BU'6C"U+ MFJU(XZ\@678D_9&D.M?/3G_@8EN_6I@SR_+1;YC';G@PX6,@$],I@.T&IG18 M-QT 4W6[0BELT*"\I!=7BX.6B!L2V'WM"-M')Y<[IK0KGXOZ5>@1SH8B2F"@ M0CV4W*Z>YZ=PW?3,&P ''EA Q=D"1 8ADE&I(/L8= M*!$DN.0MT(,*_61- ]#\FVGK CM-ILK+1[X#=B7LRAYQ&8S!9DQ[U+F/5$4O[KF_P$[S@UU0]*( M\H.ZF6,)&UCF#_$:C23#WCGK)./BM<7"4PC.I*#!J,4PIAY1Y>EY[.BBY%^?\IUZ3S[VK5(J[4^^QXA>MT'))F2C;<<,9"-$T5P/L6]-%3."2 MPM'+[C>"O51LZ7D$\%,-WH(%!,+TMQ4!)?%K[MD2+N9B<^2JT%8LE(&XX\;, MCC4HV[5&L;;#8BS :P&\>MW\%=!=W5F^K]E-9+HYX^SEX2(: @-FJ?#"I40. M!!9W$K]K5HOU&2XUA48F1QU,O9(XN]8LUE:2$'JEBJZFB5X!'.A3>>D*X.D" M)-@ZMHR@Z?^N69[EL;EVUV@A7[CL2&J\/^($^:;8"Q5;M/:H"H;3PD-98()B,V8G'A>"ML MG_K(T:(KT/L7RHWHC7:2'HMSXG;H1]4.!GDIV8%7I=>7>$?<(#I?-JN;"\!. MZO5P%$EG0@58TO.$6XC>UI4J4$M#^5G&.Q. KU8 ?J)R$SUKB*(BU:&[A(_3K)X(EY$O>T(I M71. \':EA^$,&L\BL+@EA_PA[G)-JXN#X5WQV%< MG .6I%22>LUWE7FG+"DKQ;12=R"BO,B[5KU8FG,MEQ241H-QBNPPFM.#U:[= MT/>IP2X>QCUR.=85FO-%ME/)M#3EQ-TR4W>T/2^D"#I5V[>T7+K2]K'4Q"/ MHBF(9ZA$O^I1B%3Y>ZL'[>FAB RG(M[,H"MB2#Q796*25>04H]3!B%W6:ST"S5"K5:O3K= M>18WH-ERB)60W1VVRO"F'[^A7*B4RH7J;JM0:E5*"X'*Y[8QL>=[ICISQXS[ M-3R3.H[38U:N-FNPO5T$'_PZ#,I[>A#;F>-],T_^'0HZ25^ ^/#H/+2G.GNT M=.Q4@-\1\1F[45..J8[7)TMM.[X,^P.]'-RM8+MPM_?-C ">8(;;-N8&X) M>*<(DH6A#ZZ[I\RN(FG,QR"NJ%-A&;QH:P)Q Z&GJ^K(WT[!5+R/,Y^I,SX. MCMR8UJ27&)(F7,#N=.-3/F>JW],S,$.RRDW]KA;)/6&3]X!_2Q57'@N\)6J3 MUP6)=.:?L0R?W0A_[ #)["R%ZD2,R+&KJ)2/6Q.-(FB%-%;\N"(EQJ:(F MF1MT>P.L/$[!COQFN+/=ZW&PZ*V4#A#L=QH4]I7[/2Q"!,XY-TP7$2JUF>+D M6\-9[3NLB[J01?9UM_SOKY]9N<7*K%0!MX!=CH#5HP8!X8\0'-,Q@#/IW%#I M7\PH?!I 8)N)%TLH3X=@X&](>* C@%BUKP]/ ETF6%EX="\CX"^BEHQ3#\R2 M( QH#VW7%7Y?E\:>FMZ)4+'C:+CM3R.J1?+^;D C:_QIV?]QL>Q_RG[AU*/' M\KGX.94H#VM5E1*)^*-(Q",M-NL7K6JI4CX"X8[QMW]Z0]>S?3(+Z;G=D6' M%GS>ZT5H=L$X]H'@M@GN:G(]XL..[]A]H4>]\^X@5") AQU[(I\THIVM-* ] MGUMQ0CMV.R[JG3+-4"!L@8R' F6:L)]_,OJBJ1F6'N+!]K\<+#7M]]]_.;A7 MAJX%.JK7\TFQG$E)Y8@TLUHC^ 4,Y-MY2PB,'2R'!D^!NJ$)NH)KH%,Q=.23 MP>W)E6B,I<4ZP$61ZHJF!0322M_+B=6240VH.>ES1SH(!P]Y?4O/GH],Y*C/ M*9HCGU0^SS6V:@]P*G.HKV'L:EF6,Y^+1MU;6*9*<^G-7'!?]$/JUIM0[VZ$ M%AW9GYZJ@''U>!X:C5PW$QBLF5EI9 7X:$*:X5=S(QIFGZ"XY2A(.9%863'? M00_OF6LU-RB4$U NB"#T2$*,SX$[Q%VMCV86QP>F)Y@GT\B+H.F8PDJYKM9Q MRPDE\L3C^:':YMU8:FBDRG1[&=Q!,9"TP2HV))).1(/J8Z8#OH0T:0J)?C5"- MP<35XZG0\D?;OD>#A*<:Y>\&.NX]0ZYFYB!1K6EI!/+!Q)]N^DT;_S-%!?0- M*D5,P5'VX,2F#ER_0O;EIEX\H("A##TMP$2O1U%[G'8E 6L8GDD) M#%NX8#6!\--IO6# IV<\F>D5J6E0%F#6"W'GNEJB.X#U!29)K5G(4W-NHK_D MZ%QC.; I$R M-'H?.-T$5 /\^&6)HTDY&T".AJ5%$+%-O3#:2;FY*/^ORT(.=QW'- WP0SXAFV"71Q_SLV,H&F(S7.P06Z:!Y,E8]+HH-(W@; 5M6H4FHPF 6GQ MLNB-6M_,OF!O6L?XV#=,&Z PC6^&D,/BP'4)6^#(#Z.Z+9.Z3K2I(#4??=L# M-FX[^ T(141E2,Z>61>M44WS";68Q-B>]LKU!&T=U$ZO-6.+/&;1U#LQ8@ X M^B92U4PS=YO2J'P.[#3\QLC &:5:WU+SV@.8K>1F7J2 MU$CH8@\5T7AL5\7";$_'T@D*([GIDR!A$GF+(M_7COK&/NI[HD\+"1(G-*H0 MDV/4PD.<1CNB8@98'XD'9,>0?Q,JR9[=G!SI-,$]VL88J,MB@+XP,?)I#.H M(E=1?(:^)T(_S[XAG@H48\3 #W)586*#1M/'UEC*]C0'T^4T5"N(%L4Z'9W_ M*[+/H#[&V YU-P#CSJR$VMC$N*7YVI11[?%(D2R7(CG[%'D"-RSH+;:R!WH4-TU&H$TRXFK!.OD_:00 MG\^E,8^KT_92N#0U@_<=2!8/^0'?5$]>D9B[<8THP. 3,.T'%H][>LZ82%L- M7)"(UT6XT'$\A>,NESK$:]GU.??T9[.B[E>+G3D]<=-U,!OC*+)%S\Z.[MOZ M>M#_Y0",LO_!CSPH4#5F[:G0Q#.B8;M1;NZL4G[3;-8+]5:]L>030<\1,<% M/0?_$RT\, P^4)@$(R5+_O?L5(KI.OX_BS/$F?QY(E8C\+H$D)XSM^2#E0^% M9Y\)'!"%-D9>;!2*2KID[]GL4']5C=T,!-@SQ^AH_ 3XMDFM@R\-AH;:>69Q M,;?X%X^#QP#8V)ECOK4,]IBMY)RM])RB\U1%Z'I+36=VC?RCJTBC.ORXHK/9 M^->6KG.+_Q(5;>JMQB!7HAOU;??__'I?1N5\IJ36('U)02U;&>F[2 V+85Q0 M(;OXC@?O8T +0%EPH3)[P-%&.M(']RNBT7*QA.6TQ/_LEQ+]8U+J,X6Q^X?7 M!U@;JZ7!0Y!NQ%XJ&[B7(_*G'@$XT7+"W.SP$VG5W[9^P4$LO=[6VBA@K=FPJM7J"N]^.J&N#=ARJ665 M2\W- ':[6K&:S=H*[]Z99:4UJX77SC27.JJ+.?EU,\2J-\X16L,JU7\*H3T5 MXKK5:-4W".!6R:HV*H][_P+F2!':Z/L>6VK^K$'!/II;C+HEEQ5U[?=979L8 M[C]_V?49(AF>,CQ-XRG-MR]L&SYUT\^CZ;#DGX:D1,I.1SW604SPZG*.]6K&JK-/O<$DD,#T1PK.(:/!?,E9JU6YKSJUXUS*S>M.J[NT^&>7,5 M7U5+#/W!MQ>45(]9]W6(] Q3_U1,O46?3JLYU]$%'*\CTE&W:JW&9@0/6&W7 MVFWL;@BPE8;5J#P2V)]H$[XZ-J$QE0/I@J")2FHP>AA,7D\T9+>U2B3KM007 M@-5;U4T"N%JR6HU2%@UYC=YKAJ<,3\\5#7F+L8^44:@_/YMH/Z757ZS]LO!( M%A[)PB.OR)7-,)5AZEG"(_OW?UUK'96Q&ULOF6IXECUVF72=_!PHIPHG+2:^ M8TN5^?2"^=B[^0U[R'9^%I1ANL+RGJ^WO*$BRT9IU2++VCKK(O\A+]M_GZ!T M8VLV&S]8&W@[\(5@YP#^0+$3G!&#A8[SU8]KJGI\D3W1AY].%D\=?FP5Y&93 MQX]6CJZS>/>E %Y;A6Z&X35@.$L+8*SD6G\W!CNWUA3^>(:_9:NN;=47"PG^ M,(U7UT;CGVB>AOE"TL_/#I>M1FN=^=;G@K*TN\ZRY.>!LFF5:NM,M#\/E#6K M5?V!E-NF::?U<>[1PH_%%>(/%>$\DE>2NFX"6Y?6V=WR?*#6&E:I^<)<\T10 M6W6=8M@ 4)^"U;>HC1?R].O@X4IE,QBXTGQA^^&IW+O6=K]GQ*=5?ZSHWMQ$ MX&:5,#S92\HPE&$HP]#K;YOZ8%M-^&ZMNLO9:GU^][(/GKT./ ME1M6O;X97FNY;I5V'REP?Y9N*(/*?61D^>=9!_76CSO9_W@V7O[)\=?!R VK MMB%1'8!TK7-JGC'^5 ?AN!E&?A6PNOL#;/QV]?/I<,0=/_HHC"N]?@$_^:$' M=+P.WO[UEW*]O/?K+[OE5NUIR[PT.6X>Q'6K6MJ,W-L/X/8M*NYK_%Y):+X3 MD_'STR#>;JQ2<[+S\P'=/-26RU;C1ZI0LBQ7EJ'(,)1A:',QM,E^R+JS7'(N M6OXZ3)9*Q6JU-B,Q4RE;]?(+E\@^$52<+E#:C#AAJVXU'^L@969*IF(R#&48 M^F=@:'.")^M+WI])I?27;9-/7;X.@Z1>LNH;DO"HU*W6AM0*@>U4VY#ZF^U: MQ2JW'AN6VF1?8]W?VW \_ 0VVS:>QL[K8.SRR[>./=5ZKVV&EU$%\;,9DG*[ M9E7*JU2C//#!G,S+R"S$#$,9AC800V_1R[@006R,N.!Q[##]]=[H8L"_OY8X M:+ULU9N;4818:5C-YF;8\N AU4J;X2%MUQI6K;Q*_5IFHV3Z)<-0AJ%_'H8V M.8BRQL+1V#B)P0:890/Q?_Y\QGK9*K=>>.;8 MTSZ%]^)AEZ> 6;%V7[KAY?%@OK5HRZ9]N>-G*)\,1QF.WB*.-CGJLE[#!@V: MU$=F5K%LXKLMUN'*Z?Y\=:":5B_85;]9\$9.V%RUN>8,B4BRO5 MX#Q@QF3L_2![VXX;!L)^%0S^ZNWKC,%?"X._78W^52 &A*'ZZM6Z7F(\7H6U3N*W&ZT=^OA=>K5KFT:U6:F]&E";S>JE6L1GDS*NA1 MDNZVK-)CYU]L(J_#S=$7;O''X],_X?H1?5'-?%/R_>'E\5]P\?/M^=G!_P-0 M2P,$% @ ^8!M6+;%#6U" P 6PL !$ !S<')O+3(P,C0P,S$S+GAS M9+U636_;.!"]%^A_F-5I"ZQ$R6X#6$A2=#<-$"!-"RBMH:6P32Y$J227Q MO^^0DAS%3EPG6:POICGS9MY\TH?O;RL)UVBLT.HHRI(T E2%+H5:'$6-C;DM MA(C>'[]^=?A'',/)Z=D%Q+!TKK8Y8SY"G*7SY!!^#%057HL(A5-O "A?RN:*3#;54>03T>7A=F9D MHLV"E"<-Y)0C?K9<"GF LN@1=U:H7+W=.YK.&X6Z"YXA;;F!3X]W]1:#P5'?#/V M_=/Y9>BZZ-@# $(CBJK6QD';C^>Z"&.R(Z?^5]R7(O97<3:*QUE"QB)06]1W MU!'8BXGT%7X6D75[[$W$/M;&_A#[PV/>'V[^9V=@<[1]_!,??W:P5_Q;J^$_ M8*+5Q4O)#/;;\VNB. U(6Y5PW+\N=\@7]6:_&GP>WNUTO+E+.J_!)U=*N^!H MR(37M5!SW5W1I6_BO._D*7LP(@O+\CEZ/=<)Y\+D7@Y?3N\GEVK1O!_). M>9>#\?R?PZT-/C5<@EA:\:%LCT?]9:#UY."]GRO2 '_X.CW[S2.Q?B68X[=: MZ6K5,CW11>-?H_[[@RH_*N*W.J/V,E7@%H&@YV1*ZC_V4E\S[;F62/_E1.CA M+/4?^JO76Q@>N2JA-0<#>X=LT\BF_<9B^5D=AW/!9='(=>8[<*>Q"[A9L_V1 M=\P>QW6W?=7Z66:;P]S=#(>^O6J7#OW\!5!+ P04 " #Y@&U8>^07R'H& M "Y1@ %0 '-PDF,J76T%G\QA^"GZ&).F<,T:B MB&SADC*?!=2/X#[O^!U]Y&@Q6E)3 MK!+O]_[Z='T?S,G"]]395]^M("LCZ4@F^Z]YD)Q"BP:A-$)_Y>5AGM[E]0?> ML-_=R+#S01?,SHX_)=&UVH+$PTCPB%04UH>3ZITL/MXN53S9Q(2%)%/^ILV# M+&HNR$.JJME+)"4)NC/^V L)U8 ,]8:G-W2'/ZHOOHZYPOUL*F/A!_%NO4B? M(B[RG8F)TXXAJ;?;D(X[$\&.EB^"7$=M'O"?1?0"KKYOR]A+%//T!\$7QBZR M\ID)%8X)(OA(*KSK?VL3/AT09_LFU_SWI M/=5^+:VJ2X@DUW7[=4/R;*$P5W_BR\B?V2+Y+*DE),VM<\-!%R0-0DA(?E,& M+>T,9 .-%H&T[=8-QPL6TW@[5F6$'UVI"_#F=[*UQ;(DN24\JZWPBB 77"L$ MD;!-*T!6 I(:H(HX ]Q@ZT60Z_?OAO0Y#U9Z;B:J>UN2=W-: MC8.-\_YH+K MO@X2I;DP:&5G-/';+!)IV2L.AK=$4!Y>L/!<_3A3E\=GR2V#:;;"*X(P4#4( M8C.;E@!5 W01-'P;:-W(L77_&(N%.S*C>I',XL_^PIIHJ^-A,,#-Q]W!?ZZ%2[E6AU0>"6CL?@WT6C6- >K$WUR%:K%$'VAZ M<_PEU):*M(KP(6O<(M@=[DIA7-)5*=BMAR88U^I1=$],=J\T9,^)J]"/QB^FO WF#' M!/U3&!KRSR4; EZ7 2Y %\*%'=M %>IV+A Q3WX>OA&W@C]2%M2\K5.F\1J M+S-FHOY9+!KZ1MV&^$]O;"AT\FJX0]"(E:I)J.$'<1QNN8S]Z&^ZK'^/TZSP M&D;!;,HT"#N1:&-@4&UH"-)*H$IAWK=LSD;5 %A[<7P'4!L4Q*\#_&Y.6V\ MFAKG^\>8X&41+@B7J2'Q^R0/N;XSO$VU7"2W5M]NV-X*HN>#*"R2-R'UIV/$ MS<.#_<*A2J$EC"U,\4.1+E@?4D7"6Y6!8AU("T%2R1GTIDT4@7^A$U3TKZ1< M$>$^ :=US$&Y0;-P[ 7CS@2)=I-#49:KM'Y:,A1Y934LN6XO"'!2JVGMOW! M=$+CR/H>QWY>6TN;,@/NGT0@OC\&XCN[K85]+\PHX'V9HKF_C-=6R>8SG>Q<+(F9J M:GX3?!W/U6)DZ;.:'^0MD6CU"5^U+7XPU/T97X4L$NO9@[&\$*25("N%](RO M01N&AWRV7HH[KM66_I4KV2Z:_N(1M>=_4$L#!!0 ( /F ;5@T!5J2Q@0 M $DL 5 &ULU9I=C^(V%(;O5]K_X*8W MK=00/F:W'33LBC(S*]3Y0,"V56]6)CF 5<>.;#/ O^]QP%L"819FMU7,!1^. MW^/7YW%,[.3J_2KEY F49E)T@D:M'A 0L4R8F'6"A0ZICAD+B#94))1+ 9U@ M#3IX_^[UJZOOPI!6DGL-G8 M)F,U4;PFU0S=UEN1$P6[FM6!:-G*)8W+R\LH/UJLKUE9;6R@$?UY?S>*YY#2 M$!D@LWBO*723F,_J77-OHLU!5U^SMLXCW*YAV ITI&;IHUM3W0PST MZ9Q 9IWAR:%9FG$(2+33J4SA !(FKWV'!04!K R(!!(7QG;@O^SVNPW?[2"6 M<2$-[C3.X6F(:S/Y%"7 ;(LM^\7F:),?_/&I)W'FZ$ZT430VQ3QP.VJDWZ+:>S4PWMB8J&=MEU55P(257LPN'7 KC#,V!;(\JH MPGAA/,>YSJFG2J:ER=FV)DN-2I6 Z@3-9@W/_(!DBDF%L+$D( N-7F1F75-N MC\$4E(+D;M/MHRYSBSB+:LAK?F,\F]'8PQXHROLXZE>_P?I43$?$U<5UQ+## MUO(&FYM/QIC&4VD5-=6%5/3IV+SQCLT T"M.]\DU7B"="VE/7'U:>X8=MK?> M8-O,#4.8,=M181YH>C*U ?_$,\"WC\+!()Z#.H[FKJSJZ7:^.TZ5GG,9TU4\P#6S* M-@O4ET [&J3J!(\:W^)LU3W#V4T23++>?N R&1KGH2P-4'6,I:8=PH;W")M? MB[#I(\+FOPA]6YMO>]'#KX]J+)?B10!WY9[@V[7LX/FS0B]T);\4>U0#)9^8 MW0!^"<&#&)Y@//#M6%[XR7(@M:'\+Y:=O[HHC^ )QSW7CJ(_^S)V/NDJH.=P M*VJJ2ZKHT['Q9_/%WM'B@[D49Z[S#G75973HU7'R9\/E#_1G0/1DFB[$=IFC M3X5U1%Q=8D<,.VS^;*.,)&G3XG,1JDOO.==;BA?^[*'L]::O]0+4U[,LB>,-T1+O MCJL_&RLCB!?68J,Y&3/#3[Z4/-15E]NA5\?)G]V3L:+VD;G1.IW(D__N]D35 M);1GU.'Q9W_$#;&;53RG8@;GW&XMUU875KE?Q\RW?9";%-0,Q]X')9=FCO-[ M1L69CPP="5%=@L_:=B#_AZV0J^@@-7=88!^!W1RQ;_:!3BSY!U!+ 0(4 Q0 M ( /F ;5@6NQO6^0X +!@ . " 0 !D.# Y,#8Y M9#AK+FAT;5!+ 0(4 Q0 ( /F ;5CA=KY ER( ,LQ !S<')O+3(P,C0P,S$S+GAS9%!+ M 0(4 Q0 ( /F ;5A[Y!?(>@8 +E& 5 " 5PU !S M<')O+3(P,C0P,S$S7VQA8BYX;6Q02P$"% ,4 " #Y@&U8- 5:DL8$ !) M+ %0 @ $)/ &UL4$L% 3!@ % 4 0 $ )! $! end XML 16 d809069d8k_htm.xml IDEA: XBRL DOCUMENT 0001701108 2024-03-13 2024-03-13 false 0001701108 8-K 2024-03-13 SPERO THERAPEUTICS, INC. DE 001-38266 46-4590683 675 Massachusetts Avenue 14th Floor Cambridge MA 02139 (857) 242-1600 false false false false Common Stock, $0.001 par value SPRO NASDAQ false